Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Viridian Therapeutics, Inc.\DE (VRDN) Total Liabilities (2016 - 2025)

Viridian Therapeutics, Inc.\DE has reported Total Liabilities over the past 12 years, most recently at $177.3 million for Q4 2025.

  • Quarterly results put Total Liabilities at $177.3 million for Q4 2025, up 150.48% from a year ago — trailing twelve months through Dec 2025 was $177.3 million (up 150.48% YoY), and the annual figure for FY2025 was $177.3 million, up 150.48%.
  • Total Liabilities for Q4 2025 was $177.3 million at Viridian Therapeutics, Inc.\DE, up from $74.2 million in the prior quarter.
  • Over the last five years, Total Liabilities for VRDN hit a ceiling of $177.3 million in Q4 2025 and a floor of $16.0 million in Q4 2021.
  • Median Total Liabilities over the past 5 years was $42.6 million (2022), compared with a mean of $48.2 million.
  • Biggest five-year swings in Total Liabilities: dropped 1.85% in 2022 and later surged 150.48% in 2025.
  • Viridian Therapeutics, Inc.\DE's Total Liabilities stood at $16.0 million in 2021, then skyrocketed by 150.28% to $40.0 million in 2022, then grew by 20.92% to $48.4 million in 2023, then surged by 46.2% to $70.8 million in 2024, then surged by 150.48% to $177.3 million in 2025.
  • The last three reported values for Total Liabilities were $177.3 million (Q4 2025), $74.2 million (Q3 2025), and $67.2 million (Q2 2025) per Business Quant data.